Clinical Trials · NCT00412061
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 429
- Start date
- Dec 2006
- Locations
- 70 sites, 15 countries
- Primary endpoint
- Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review